US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

登録

NXTC

NextCure (NXTC)

NextCure Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:NXTC

1 2 3 4 5 6 7 8 9 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/31	05 : 05	GlobeNewswire Inc.	NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024	NASDAQ:NXTC	NextCure Inc
2024/05/03	05 : 05	GlobeNewswire Inc.	NextCure Provides Business Update and Reports First Quarter 2024 Financial Results	NASDAQ:NXTC	NextCure Inc
2024/04/25	05 : 05	GlobeNewswire Inc.	NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024	NASDAQ:NXTC	NextCure Inc
2024/04/08	20 : 00	GlobeNewswire Inc.	NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024	NASDAQ:NXTC	NextCure Inc
2024/04/04	20 : 05	GlobeNewswire Inc.	NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board	NASDAQ:NXTC	NextCure Inc
2024/04/02	20 : 00	GlobeNewswire Inc.	NextCure to Present at 23rd Annual Needham Virtual Healthcare Conference	NASDAQ:NXTC	NextCure Inc
2024/03/21	21 : 55	GlobeNewswire Inc.	NextCure Provides Business Update and Reports Full Year 2023 Financial Results	NASDAQ:NXTC	NextCure Inc
2024/03/05	22 : 05	GlobeNewswire Inc.	NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances	NASDAQ:NXTC	NextCure Inc
2024/02/02	06 : 45	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NXTC	NextCure Inc
2024/02/02	06 : 45	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NXTC	NextCure Inc
2024/02/02	06 : 44	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NXTC	NextCure Inc
2024/02/02	06 : 44	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NXTC	NextCure Inc
2024/02/02	06 : 43	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NXTC	NextCure Inc
2024/02/02	06 : 43	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NXTC	NextCure Inc
2024/01/19	06 : 05	GlobeNewswire Inc.	NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders	NASDAQ:NXTC	NextCure Inc
2023/12/21	21 : 05	GlobeNewswire Inc.	NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury	NASDAQ:NXTC	NextCure Inc
2023/12/14	21 : 15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NXTC	NextCure Inc
2023/12/14	20 : 45	GlobeNewswire Inc.	NextCure Provides Year-End Clinical Pipeline Updates	NASDAQ:NXTC	NextCure Inc
2023/11/20	21 : 00	GlobeNewswire Inc.	NextCure to Present at the 35th Annual Piper Sandler Healthcare Conference	NASDAQ:NXTC	NextCure Inc
2023/11/16	06 : 05	GlobeNewswire Inc.	NextCure Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AML	NASDAQ:NXTC	NextCure Inc
2023/11/03	05 : 20	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:NXTC	NextCure Inc
2023/11/03	05 : 10	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NXTC	NextCure Inc
2023/11/03	05 : 05	GlobeNewswire Inc.	NextCure Provides Business Update and Reports Third Quarter 2023 Financial Results	NASDAQ:NXTC	NextCure Inc
2023/10/17	21 : 05	GlobeNewswire Inc.	Preclinical Data Demonstrate Anti-Siglec-15 Treatment Reduced Bone Loss and Enhanced Bone Quality in Mice with Moderate-to-Severe Osteogenesis Imperfecta (OI)	NASDAQ:NXTC	NextCure Inc
2023/09/27	05 : 05	GlobeNewswire Inc.	NextCure Presents Preclinical Data on NC181, a Novel Therapeutic Candidate Targeting ApoE4, for the Treatment of Alzheimer’s Disease	NASDAQ:NXTC	NextCure Inc
2023/09/12	21 : 05	GlobeNewswire Inc.	A Phase 2 Study of Anti-Siglec-15 Antibody, NC318, in Combination with Pembrolizumab (NCT04699123) Demonstrates Clinical Activity in Patients with Advanced PD-1 Axis Inhibitor Refractory NSCLC	NASDAQ:NXTC	NextCure Inc
2023/09/08	05 : 05	GlobeNewswire Inc.	NextCure and Nordic Bioscience Publish Review Article on the Regulation of Tumor Immunity by Tumor Collagen	NASDAQ:NXTC	NextCure Inc
2023/09/06	05 : 05	GlobeNewswire Inc.	Preclinical Data Demonstrate Potential Application of Anti-Siglec-15 Treatment in Bone Disease	NASDAQ:NXTC	NextCure Inc
2023/08/31	20 : 00	GlobeNewswire Inc.	NextCure to Present at the H.C. Wainwright 25th Annual Global Investment Conference	NASDAQ:NXTC	NextCure Inc
2023/08/05	05 : 58	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:NXTC	NextCure Inc

Showing the most relevant articles for your search:NASDAQ:NXTC

1 2 3 4 5 6 7 8 9 次へ >>

Gold vs US Dollar

American Express

Bank of America

US Dollar vs Sterling

JP Morgan Chase

Invesco QQQ Trust Series 1

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約